XWELL, Inc. (XWEL) 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for XWELL, Inc. for the fiscal year ended December 31, 2024. XWELL is a global wellness company operating four reportable segments: XpresSpa (airport spa services), XpresTest (bio-surveillance and former diagnostic testing), Naples Wax Center (off-airport hair removal and skincare), and Treat (travel wellness centers). The company is headquartered in New York, NY, and trades on the Nasdaq Capital Market under the symbol "XWEL."
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $33.9 million | $30.1 million |
| Gross Profit | $8.9 million | $3.7 million |
| Operating Loss | $(16.7) million | $(28.2) million |
| Net Loss | $(16.5) million | $(28.0) million |
| Net Loss Attributable to XWELL | $(16.9) million | $(27.7) million |
| Cash and Cash Equivalents | $4.6 million | $8.4 million |
| Marketable Securities | $7.2 million | $14.6 million |
| Total Current Assets | $15.3 million | $26.6 million |
| Total Current Liabilities | $9.2 million | $9.3 million |
| Working Capital | $6.1 million | $17.2 million |
| Net Cash Used in Operating Activities | $(11.0) million | $(16.1) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13% to $33.9 million, driven primarily by a full year of service revenue from the Naples Wax acquisition and growth in XpresSpa's new touchless locations.
- Cost Reductions: Cost of sales decreased by $1.5 million due to the closure of underperforming XpresSpa locations. General and administrative expenses decreased by 3% due to cost optimization, partially offset by approximately $2.1 million in one-time legal fees related to the CPC lawsuit defense.
- Impairment Charges: Total impairment charges decreased significantly compared to 2023. In 2024, the company recorded $1.7 million in long-lived asset impairments and $2.8 million in operating lease right-of-use asset impairments. In contrast, 2023 included a $4.0 million goodwill impairment charge related to the HyperPointe business.
- Segment Performance: XpresTest transitioned from a loss of $4.7 million in 2023 to an operating income of $5.2 million in 2024, largely due to expanded CDC bio-surveillance contracts. XpresSpa operating loss narrowed from $13.0 million to $12.3 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern. The company has suffered recurring losses and insufficient liquidity to fund future operations without raising additional capital. Management does not currently have sufficient liquidity to fund operations for the next 12 months.
- Capital Raises: In January 2025, the company completed a private placement of Series G Convertible Preferred Stock and warrants, raising $4.0 million. In August 2024, a registered direct offering raised approximately $1.4 million.
- Strategic Outlook: Management plans to right-size the airport portfolio, pursue off-airport growth (specifically in the med-spa sector), and expand international bio-surveillance services. The Treat segment is being phased out, with the final location converting to an XWELL brand location in mid-2025.
- Internal Control Weaknesses: The company identified five material weaknesses in internal controls over financial reporting, including deficiencies in lease accounting, revenue processes, and controls over foreign subsidiaries. Remediation efforts are underway.
- Legal Proceedings: A significant lawsuit filed by CPC Pain & Wellness SPV, LLC regarding board fiduciary duties was dismissed in August 2024. An arbitration regarding Atlanta airport concessions is ongoing.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.0 million raised in January 2025 against the company's stated need for additional capital to fund operations for the next 12 months.
- Internal Controls: Monitor the progress of remediation for the five identified material weaknesses in internal controls over financial reporting.
- Segment Viability: Assess the sustainability of XpresTest's profitability, which is heavily reliant on government contracts (CDC/Ginkgo Bioworks) that are subject to renewal and funding changes.
- Asset Impairments: Review future impairment risks for XpresSpa locations, given the history of lease and asset write-downs in underperforming airports.
- Dilution Risk: Evaluate the potential dilution from the Series G Preferred Stock conversion and the exercise of warrants issued in the January 2025 private placement.